NCT04246190Unknown1 期
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of CKD-501 and D759 in Healthy Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Cmax of CKD-501, D759 and CKD-396
研究概览
简要总结
The purpose of this study is to evaluate the pharmacokinetics and safety of CKD-396.
详细描述
Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of CKD-501 and D759 in Healthy Adults
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult who is 19 ~ 55 years at the time of screening
- •Body weight more than 55 kg for male and more than 50kg for female
- •BMI more than 18.5 kg/m2 or less than 27.0 kg/m2
- •Females must be menopause or surgical infertility
- •Males who have consented to the use of appropriate pregnancy contraceptive methods up to 28 days after the last investigational product and not to provide sperm
- •Subjects who voluntarily decided to participate and informed consent based upon understanding on the study.
排除标准
- •Subjects who have a history of clinically significant hepatic, renal, nervous, immune, respiratory, urinary, digestion, endocrine, hematooncology, cardiovascular systemic disease or psychosis disorder
- •Subjects who have diabetic ketoacidoisis, diabetic coma, diabetic precoma, Type 1 diabetes
- •Subjects who have genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •Subjects who have a history of gastrointestinal disorders (Crohn's disease, ulcerative colitis, etc.) or surgery (except simple appendectomy or hernia surgery) that may affect the absorption of the drug
- •Subjects who have a history of clinically significant hypersensitivity to drugs or additives, including components of the investigational product(lobeglitazone, sitagliptin) and same class drug with thiazolidinediones
- •Subjects who have severe infectious disease and severe trauma before and after operation
- •Subjects who are deemed unsuitable as subjects in the screening test performed within 28 days before the administration of investigational product
- •AST, ALT> UNL(Upper Normal Limit)x1.25
- •Total bilirubin > UNL(Upper Normal Limit)x1.5
- •eGFR (Estimated Glomerular Filtration Rate) <60 mL/min/1.73m2 using the MDRD (Modification of Diet in Renal Disease) formula
- •Positive immunologic serological tests (hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test, syphilis test)
- •After resting for more than 5 minutes, systolic blood pressure> 150 mmHg or < 90 mmHg, diastolic blood pressure> 100 mmHg or <50 mmHg
- •Subjects who have had a history of drug abuse within one year of screening or have tested positive on urine drug screening test
- •Pregnant or lactating women
- •Subjects who have consistently excessively smoked or consumed caffeine or alcohol (caffeine:> 5 cups / day, alcohol:> 210 g / week, cigarettes:> 10 cigarettes / day) or cannot stop smoking, consuming caffeine and alcohol during hospitalization
- •Subjects who judged to able to affect in the study or in the subject's safety by the investigator for the following reasons
- •Ethical-the-counter (ETC) drugs and herbal medicines within 14 days of the first administration of the investigational drug.
- •Over-the-counter (OTC) drugs, including health foods and vitamin preparations, within 7 days of the first dose of the investigational product
- •Subjects who have received the investigational product by participating in other clinical trials (including bioequivalence studies) within 180 days before the first dose of the investigational product (For biological agents, this may be based on a longer period of time, considering the half-life)
- •Subjects who donated whole blood within 60 days before the first dose of the investigational product or donated component blood donation within 30 days
- •Subjects who received a blood transfusion within 60 days before the first dose of the investigational product
- •Subjects who were deemed to be inappropriate to participate in the study by the investigator judgment
研究组 & 干预措施
Group 2
Experimental
- Period 1: CKD-396
- Period 2: CKD-501 and D759
干预措施: CKD-396 (Drug)
Group 1
Experimental
- Period 1: CKD-501 and D759
- Period 2: CKD-396
干预措施: CKD-501 and D759 (Drug)
Group 1
Experimental
- Period 1: CKD-501 and D759
- Period 2: CKD-396
干预措施: CKD-396 (Drug)
Group 2
Experimental
- Period 1: CKD-396
- Period 2: CKD-501 and D759
干预措施: CKD-501 and D759 (Drug)
结局指标
主要结局
Cmax of CKD-501, D759 and CKD-396
时间窗: 0(predose)~48 hours
Maximum plasma concentration of CKD-501, D759 and CKD-396
AUClast of CKD-501, D759 and CKD-396
时间窗: 0(predose)~48 hours
Area under the plasma concentration-time curve to last concentration of CKD-501, D759 and CKD-396
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375Type2 Diabetes MellitusNCT04221360Chong Kun Dang Pharmaceutical26
已完成
1 期
A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.Type2 Diabetes MellitusNCT04810676Chong Kun Dang Pharmaceutical27
Unknown
1 期
Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male AdultsDyslipidemiasHypertensionNCT03849287Chong Kun Dang Pharmaceutical36
已完成
1 期
Study to Compare the Safety and Pharmacokinetics of CKD-397Benign Prostatic HyperplasiaNCT02645890Chong Kun Dang Pharmaceutical36
已完成
1 期
Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - BHypertensionNCT02811731Chong Kun Dang Pharmaceutical32